Citations

Clear

36 citation(s) found for "Sattler, L".

Improving Preparatory Materials for the Pediatric Infectious Diseases Initial Certifying Exam: A Targeted Needs Assessment
Sattler, Matthew M , Ristagno, Elizabeth H. , Boguniewicz, Juri , Fatemi, Yasaman , Jamal, Hassan H. , Vidal, Diego A Cruz , Boguniewicz, Juri , Jamal, Hassan, Parzen-Johnson, Simon

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | May 25, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1093/jpids/piaf048 | PMID 40413637 Get It

Abstract We conducted a national survey of current pediatric infectious diseases (PID) fellows and PID fellowship graduates from the past 10 years to assess satisfaction with existing PID initial certifying exam preparatory materials. Satisfaction with existing resources was low. The most desired new resource was additional board-style questions.
Barriers to global engagement for African researchers: A position paper from the Alliance for Medical Research in Africa (AMedRA)
Gaye, Bamba , Singh, Gurbinder , Gaye, Ngone Diaba, Ka, Mame Madjiguène , Seck, Daouda, Gueye, Khadidiatou, Kitara, David Lagoro , Lassale, Camille , Anne, Malick, Diaw, Mor , Gaye, Magaye, Fall, Abdou Salam , Diongue, Aïda, Seck, Ibrahima , Belkhadir, Jamal , Wone, I, Gueye, Sérigne Maguèye , Sow, Papa Salif , Kohen, Jamal Eddine, Vogelsang, Dorothea, Mbaye, Maïmouna Ndour, Liyong, Elisabeth Alice, Kengne, André Pascal , Sougou, Ndèye Mariéme, Ba, Awa, Tukakira, John, Lorenz, Thiess , Kabore, Elisé , Muzumala, Malaizyo Gabriel, Olanrewaju, A. I., Jaiteh, Lamin , Délicat-Loembet, Lucrèce M. , Alson, Aimée Olivat Rakoto, Niang, Khadim, Mwebaze, Ernest , Nakatumba‐Nabende, Joyce , Machuve, Dina , Adie, Prestone, Hanne, Fatoumata, Sougou, Marième, Koffi, Kouassi Gustave, Luwanda, Lameck, Mekonnen, Demeke, Ebeid, Fatma Soliman Elsayed , Enama, Jean Paul, Zeba, Mohamadi , Guedou, Fernand Aimé, Mbélesso, Pascal , Carter, Jennifer , Coulibaly, Bakary, Dramé, Mohamed Lamine, Mouanga, Alain Maxime , Lacroix, Philippe, Diagana, Mouhamadou , Ekouévi, Didier Koumavi , Houinato, Dismand, Faye, Adama , Wambugu, Vivien , Kamaté, Jean, Lalika, Mathias , Ale, Boni Maxime , Fall, Ibrahima Socé , Samb, Abdoulaye, Jobe, Modou , Isiozor, Nzechukwu Michael , Gaye, Ngone Diaba, Seck, Daouda , Seck, Sidy Mohamed , Sow, Abdourahmane , Diongue, Aïda, Lamptey, Roberta , Sobngwi, Eugène , Muzumala, Malaizyo G. , Maina, Ciira wa , Adie, Prestone, Tine, Roger Clément Kouly , Koffi, K. G. , Sattler, Elisabeth Lilian Pia , Enama, Jean-Paul, Coulibaly, Bakary, Preux, Pierre‐Marie , Nsoesie, Elaine Okanyene , Tshilolo, Léon Muepu

Mayo Clinic

Journal of Global Health | October 18, 2024 | Volume: 14 | Issue: No issue available | Pages: No page available

10.7189/jogh.14.03042 | PMID 39421942 Get It

Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
Büyüközkan, Mustafa , Doraiswamy, P. Murali , Wu, Tong , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Krumsiek, Jan, Arnold, Matthias , Nho, Kwangsik T. , Guðnason, Vilmundur , Launer, Lenore J. , Wang‐Sattler, Rui , Adamski, Jerzy , Bennett, David A. , Saykin, Andrew J. , Peters, Annette , Suhre, Karsten , Kaddurah‐Daouk, Rima , Kastenmüller, Gabi

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.072776 Get It

AbstractBackgroundBrain glucose hypometabolism is among the earliest pathogenic changes in Alzheimer’s disease (AD). This metabolic dysfunction points to the personal bioenergetic capacity, defined as the ability to maintain energy homeostasis under all circumstances including deregulated glucose uptake, as a potential source of resilience to the disease. Fasting blood acylcarnitine profiles are a central readout for this capacity in the absence of dietary glucose and capture the activity and efficiency of glucose‐independent routes of mitochondrial energy metabolism.MethodWe used fasting serum acylcarnitine profiles of 1,531 participants (465 with normal cognition, 762 with mild cognitive impairment, and 304 with clinical AD) from the AD Neuroimaging Initiative to perform unsupervised subgroup identification using hierarchical clustering. Identified subgroups were investigated for differences in A/T/N biomarker profiles and cognitive status. The contributions of genetic and potentially modifiable factors defining the subgroups were quantified using analysis of explained variance. The influence of the strongest determining factors on longitudinal cognitive trajectories was estimated using linear mixed‐effects models and gene‐by‐environment interaction analysis.ResultWe found several bioenergetically distinct subgroups with significant differences in AD biomarker profiles and cognitive function. The strongest genetic contribution to this bioenergetic endophenotype seems to be specifically linked to succinylcarnitine metabolism and significantly modulates the rate of future cognitive decline. In contrast, potentially modifiable sustainment of beta‐oxidation efficiency seems to decelerate bioenergetic aging, thus creating a bioenergetic reserve that delays progression of cognitive decline. Using gene‐by‐environment interaction analysis, we demonstrate that this molecular framework identifies a subgroup of individuals that is likely to benefit significantly from personalized therapeutic, dietary or lifestyle interventions tailored to increase resilience against bioenergetic disturbances in AD.ConclusionOur study reports on a set of genetic and metabolic markers that define bioenergetically distinct subgroups with significant differences on the AD biomarker and cognitive level. Longitudinal data suggest that targeting the modifiable fraction of this endophenotype might be a promising strategy to slow down disease progression in individuals with specific allelic configurations.
Laying the Groundwork for a Fulfilling Career in Pediatric Infectious Diseases: The Transition From Fellowship to Faculty
Kushner, Lauren E. , Ristagno, Elizabeth H. , Dong, Sara W , Konold, Victoria , Fatemi, Yasaman , Stillwell, Terri, Wohrley, Julie, Sattler, Matthew M , Kalu, Ibukunoluwa C. , Boguniewicz, Juri , Boguniewicz, Juri

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | October 10, 2023 | Volume: 12 | Issue: 12 | Pages: 627-633

10.1093/jpids/piad079 | PMID 37815429 Get It

Abstract There are limited resources for guidance on the transition from fellowship into a new faculty role in pediatric infectious diseases. This review aims to address this gap and provides a framework for a successful transition that is composed of four essential pillars—(1) stepping into your role, (2) finding your niche, (3) building your network, and (4) self-care—all of which are supported by strong mentorship/sponsorship and continual realignment with one’s personal mission statement. In addition to providing general principles and guidance, this review also outlines specific steps that a junior faculty member can take to expand their influence and build a successful, fulfilling career in pediatric infectious diseases.
Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers
Korzun, Tetiana , Moses, Abraham S. , Diba, Parham , Sattler, Ariana , Olson, Brennan , Taratula, Olena R. , Marks, Daniel L. , Taratula, Oleh , Sattler, Ariana L , Marks, Daniel L , Taratula, Oleh , Taratula, Oleh , Olson, Brennan G , Pejovic, Tanja B.

Mayo Clinic

Small | July 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/smll.202301776 | PMID 37518857 Get It

AbstractGynecological malignancies are a significant cause of morbidity and mortality across the globe. Due to delayed presentation, gynecological cancer patients are often referred late in the disease's course, resulting in poor outcomes. A considerable number of patients ultimately succumb to chemotherapy‐resistant disease, which reoccurs at advanced stages despite treatment interventions. Although efforts have been devoted to developing therapies that demonstrate reduced resistance to chemotherapy and enhanced toxicity profiles, current clinical outcomes remain unsatisfactory due to treatment resistance and unfavorable off‐target effects. Consequently, innovative biological and nanotherapeutic approaches are imperative to strengthen and optimize the therapeutic arsenal for gynecological cancers. Advancements in nanotechnology‐based therapies for gynecological malignancies offer significant advantages, including reduced toxicity, expanded drug circulation, and optimized therapeutic dosing, ultimately leading to enhanced treatment effectiveness. Recent advances in nucleic acid therapeutics using microRNA, small interfering RNA, and messenger RNA provide novel approaches for cancer therapeutics. Effective single‐agent and combinatorial nucleic acid therapeutics for gynecological malignancies have the potential to transform cancer treatment by giving safer, more tailored approaches than conventional therapies. This review highlights current preclinical studies that effectively exploit these approaches for the treatment of gynecological malignant tumors and malignant ascites.
Update of penetrance estimates in Birt-Hogg-Dubé syndrome
Bruinsma, Fiona , Dowty, James G., Win, Aung Ko , Goddard, Laura C, Agrawal, Prachi , Attinà, Domenico , Bissada, Nabil K., Eisen, Daniel B. , Furuya, Mitsuko , Hansen, Thomas van Overeem , Houweling, Arjan C. , Johannesma, Paul C., Lim, Derek H.K., Lindor, Noralane M. , Luzzi, Valentina , Lynch, Maeve , Maffé, Antonella, Menko, Fred H. , Michels, Guido, Pulido, José S. , Ryu, Jay H. , Sattler, Elke , Steinlein, Ortrud K. , Tucker, Kathy , Beek, Irma van de , Riel, Lore van , Zénone, Thierry, Zompatori, Maurizo, Bondavalli, Davide , I-CONFIRM, Genetic Susceptibility Working Group, Bruinsma, Fiona Jane , Turchetti, Daniela , Maher, Eamonn R , Win, Aung K , Ryu, Jay H , Hansen, Thomas van Overeem , Luise, Monica De , Gasparre, Giuseppe , Genuardi, Maurizio , Gerdes, Anne‐Marie , Lencastre, André , Tomassetti, Sara , Steensel, Maurice A. M. Van , Zompatori, Maurizio , Walsh, Jennifer, Maher, Eamonn R. , Winship, Ingrid , I-CONFIRM, Genetic Susceptibility Working Group

Mayo Clinic

Journal of Medical Genetics | February 27, 2023 | Volume: 60 | Issue: 4 | Pages: 317-326

10.1136/jmg-2022-109104 | PMID 36849229 Get It

Background Birt-Hogg-Dubé (BHD) syndrome is a rare genetic syndrome caused by pathogenic or likely pathogenic germline variants in the FLCN gene. Patients with BHD syndrome have an increased risk of fibrofolliculomas, pulmonary cysts, pneumothorax and renal cell carcinoma. There is debate regarding whether colonic polyps should be added to the criteria. Previous risk estimates have mostly been based on small clinical case series. Methods A comprehensive review was conducted to identify studies that had recruited families carrying pathogenic or likely pathogenic variants in FLCN . Pedigree data were requested from these studies and pooled. Segregation analysis was used to estimate the cumulative risk of each manifestation for carriers of FLCN pathogenic variants. Results Our final dataset contained 204 families that were informative for at least one manifestation of BHD (67 families informative for skin manifestations, 63 for lung, 88 for renal carcinoma and 29 for polyps). By age 70 years, male carriers of the FLCN variant have an estimated 19% (95% CI 12% to 31%) risk of renal tumours, 87% (95% CI 80% to 92%) of lung involvement and 87% (95% CI 78% to 93%) of skin lesions, while female carriers had an estimated 21% (95% CI 13% to 32%) risk of renal tumours, 82% (95% CI 73% to 88%) of lung involvement and 78% (95% CI 67% to 85%) of skin lesions. The cumulative risk of colonic polyps by age 70 years old was 21% (95% CI 8% to 45%) for male carriers and 32% (95% CI 16% to 53%) for female carriers. Conclusions These updated penetrance estimates, based on a large number of families, are important for the genetic counselling and clinical management of BHD syndrome.
The subjectively perceived injectability as an early indicator for adverse events?
Alfertshofer, Michael , Sattler, Gerhard, Frank, Konstantin , Melnikov, Dimitry V., Freytag, Lysander, Mercado‐Perez, Arnaldo , Hargiss, J. Blade , Cotofana, Sebastian , Alfertshofer, Michael , Hargiss, John Blade , Dumbrava, Mihai , Cotofana, Sebastian , Dumbravă, Mihai

Mayo Clinic

Journal of Cosmetic Dermatology | February 7, 2022 | Volume: 21 | Issue: 9 | Pages: 3943-3948

10.1111/jocd.14697 | PMID 35128773 Get It

AbstractBackgroundWith an increasing demand of aesthetic soft‐tissue filler treatments, the occurrence of adverse events rises likewise. An optimized injection algorithm adapted to product characteristics (eg, rheology) of the soft‐tissue filler is crucial in order to ensure satisfying clinical outcomes and high patient safety.ObjectiveTo identify a subjective feedback mechanism for the avoidance of adverse events after soft‐tissue filler injection procedures.MethodsA retrospective data analysis of n = 387 aesthetic treatments performed on n = 291 patients (4 males, 287 females) with different soft‐tissue fillers with regard to loss of volume (filling effect), injected layer, injectability (“ease of injection”), injected volume, and injection technique was conducted.ResultsThe subjectively perceived injectability during the injection process was statistically significantly related to G‐Prime value with rs = 0.101 with p = 0.048, indicating an increased difficulty while injecting products with higher G‐Prime. The occurrence of adverse events was also statistically significantly related to the injectability: injections with increased subjectively perceived difficulty showed increasing odds of developing adverse events by OR 0.157 with p = 0.002.ConclusionInjections that were subjectively more difficult to perform are more likely to develop adverse events. Respecting the layered arrangement of the face, the recommended and approved depth and facial region for each specific treatment enable practitioners to achieve satisfying outcomes while keeping the rate of adverse events low.
Validated 5 – Point photonumeric scales for the assessment of hand atrophy
Pavicic, Tatjana , Pooth, Rainer, Prinz, Valentina, Cajkovsky, Mia, Hernandez, Claudia A, Mueller, Daniel S., Sattler, Sonja , Klepetko, Heike , Kerscher, Martina , Fabi, Sabrina G. , Frank, Konstantin , Day, Doris , Cotofana, Sebastian , Frank, Konstantin , Green, Jeremy B. , Mueller, Daniel S., Suwanchinda, Atchima , Cotofana, Sebastian

Mayo Clinic

Journal of Cosmetic Dermatology | January 16, 2022 | Volume: 21 | Issue: 3 | Pages: 933-939

10.1111/jocd.14776 | PMID 35034418 Get It

AbstractObjectiveQuantifying the degree of dorsal hand atrophy is a challenging endeavor, but often necessary, in both the clinical and the research setting. The aim of this investigation was to create and consecutively validate a 5‐point photonumeric scale for assessment of dorsal hand atrophy.Material and MethodsA medical team created a novel 5‐point photonumeric scale. Twelve international raters were involved in the digital validation, while five raters performed a live validation.ResultsFor the digital validation of the Croma Hand Atrophy Assessment Scale, a total of 72 subjects (58 females, 14 males) with a mean age of 43.0 ± 14.4 years [18–73 years] were assessed. For the live validation, 88 subjects (73 females, 15 males) with a mean age of 45.0 ± 14.1 years [20–73 years] were rated. The results revealed almost perfect intra‐rater (ICC: 0.90 [95% CI: 0.88–0.92]) and inter‐rater agreements (ICC: 0.85 [95% CI: 0.81–0.89] and 0.86 [95% CI:0.82–0.89]) in the digital validation and substantial intra‐rater (ICC: 0.79 [95% CI: 0.75–0.82]) and inter‐rater agreements (ICC: 0.75 [95% CI: 0.68–0.81] and ICC: 0.67 [95% CI: 0.54–0.77]) in the live validation.ConclusionThe created scale to assess dorsal hand atrophy has been shown to provide substantial‐to‐almost perfect agreement in the digital and live validation cycles and reached comparable intra‐rater and inter‐rater agreement to already published and validated scales. It is expected that the created scale will help physicians and researchers in the assessment of hand atrophy in the clinical and research setting in the future.